Adaptive Biotechnologies

Guardant Health

Short interest: 7.56% of float, squeeze risk: MODERATE

929 PubMed publications found for Adaptive Biotechnologies

Multiscale predictive cellular modeling: integrating hypothesis grammars, digital twins, and multi-omics for In silico oncology and precision theranostics.

Impact of Insecticide-Treated Nets on Plasmodium falciparum Infection Rates: A Meta-Analysis.

Human sand fly challenge elicits saliva-specific innate and type 1-polarized immunity that promotes Leishmania killing.

Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial.

Efficient and robust generation of functional hematopoietic cells from human pluripotent stem cells in albumin-free conditions.

925 PubMed publications found for Adaptive Biotechnologies

924 PubMed publications found for Adaptive Biotechnologies

A next-generation SPE-enabled microfluidic device for the rapid screening of antibiofilm compounds.

927 PubMed publications found for Adaptive Biotechnologies

Suppressive effect of lemon (Citrus limon L. Burm. f.) extract toward pro-tumor immune response in DMBA-induced carcinogenesis mouse.

SW convergence: 36/100 (Bearish Convergence), 1 bullish / 1 bearish signals

923 PubMed publications found for Adaptive Biotechnologies

Deep Tumor Penetration Using Nanoparticle Delivery Systems: Programmed Design Strategies and Emerging Evaluation Platforms.

922 PubMed publications found for Adaptive Biotechnologies

SW convergence: 41/100 (Bearish Convergence), 2 bullish / 2 bearish signals

Precision oncology in the age of AI: lessons from AI-driven drug discovery and clinical translation.

921 PubMed publications found for Adaptive Biotechnologies

Developing MRD as an early endpoint for accelerated approval in CLL.

920 PubMed publications found for Adaptive Biotechnologies

Novel paracellular marker based on ᴅ-dipeptide structure for highly sensitive quantification with UPLC-MS/MS for in vitro and in vivo blood-brain barrier permeability analysis.

919 PubMed publications found for Adaptive Biotechnologies

Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study.

Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial.

915 PubMed publications found for Adaptive Biotechnologies

SW convergence: 55/100 (Neutral), 2 bullish / 1 bearish signals

<article class="bts-verified-summary" data-ticker="ADPT">
<p>Adaptive Biotechnologies (ADPT) is the lead sponsor of 1 active clinical trials listed on ClinicalTrials.gov<sup><a href="#fn-1">[1]</a></sup>.</p>
<p>ADPT has 17 Form 4 insider filings recorded at the SEC in the past 30 days<sup><a href="#fn-2">[2]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">ClinicalTrials.gov (2026-04-11) <a href="https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Adaptive+Biotechnologies%22&amp;aggFilters=status%3Arec%2Cact" rel="nofollow noopener noreferrer">↗</a></li>
<li id="fn-2">SEC EDGAR · 0001478320 (2026-04-11) <a href="https://efts.sec.gov/LATEST/search-index?q=%22ADPT%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-03-12&amp;enddt=2026-04-11" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>

ClinicalTrials.gov

SEC EDGAR — 0001478320

Adaptive Biotechnologies (ADPT) — BioTechSigns Verified Summary

Adaptive Biotechnologies (ADPT) is the lead sponsor of 1 active clinical trials listed on ClinicalTrials.gov[1].

ADPT has 17 Form 4 insider filings recorded at the SEC in the past 30 days[2].

Sources:
[1] ClinicalTrials.gov. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Adaptive+Biotechnologies%22&aggFilters=status%3Arec%2Cact
[2] SEC EDGAR, 0001478320. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://efts.sec.gov/LATEST/search-index?q=%22ADPT%22&forms=4&dateRange=custom&startdt=2026-03-12&enddt=2026-04-11

In this study, invesigators propose to analyze 150 DLBCL patients, 50 MCL patients, and 100 FL patients to determine the clinical utility of ctDNA- as well as circulating tumor cell (CTC)-based MRD assessment in CAR therapy patients. The project detailed in this protocol will utilize the clonoSEQ platform as specific quantification of residual DLBCL/FL/MCL and correlate its results with radiologic assessment of disease and clinical outcomes. Invesitgators predict there will be a strong correlation between ctDNA and PET/CT and dynamic changes in ctDNA will precede radiologic evidence of disease recurrence in patients following CAR therapy.